Multimodal Continuing Education Improves Knowledge and Clinical Skills in Moderate to Severe Atopic Dermatitis Among US Healthcare Professionals

Leen Alyaseen, PharmD, MBA; Sarah Nisly, PharmD, MEd, BCPS, FCCP; Rick Daigle, PT, DPT, EdD; Robin Black, PharmD, BCACP; Sowmya Daram, Mpharm; Adedayo Akinpelu, PharmD

Background

- **Atopic dermatitis (AD) is chronic disease that affects up to 7.6%** of US adults.[1]
- Guidelines recommend IL-13–targeted biologics for adults with moderate to severe AD requiring systemic treatment.[2]
- Healthcare professional knowledge gaps may delay biologic escalation, supporting CE for dermatology and allergy teams.[3]

Objective

- **Evaluate knowledge and clinical skill gains** among US healthcare professionals following a multimodal CE program on advanced biologic therapies for moderate to severe AD

Methods

- 16 activities across 5 formats, released March-July 2025
- Data collection: March 21, 2025, to September 25, 2026

Data Collection

6 Chapter Meetings + **1** Webinar

3 Video Modules

3 Interactive Cases

2 ClinicalThought Commentaries

1 Slide Player

Statistical Analysis

- Pooled pre/post responses compared using chi-square tests


Overall Program Metrics

Program Reach


461 Live Learners

6747 Enduring Learners

Top Professions




Top Specialties




The Biggest Educational Gain: Classifying Which Patients With AD Qualify for Biologic Therapy

Live Performance Across All Learning Objectives



Enduring Performance Across All Learning Objectives



n = number of learner responses

Educational Program Impact

At baseline, many learners reported limited confidence in identifying candidates for IL-13–targeted biologics. After education, candidate classification showed the greatest learning gains (+26 percentage points live; +21 enduring).

71% increased **awareness** of foundational knowledge

45% increased likelihood of **adoption** of principles

39% improved **application** of practices

25% prioritized **application** of educational content

Themes in learner comments and questions

Choosing among biologics
IL-13 vs IL-4/IL-13 and real-world evidence, therapies, comparative

Switching treatment
When to change biologics or move to a JAK inhibitor

Assessing individual safety
Conjunctivitis, cardiovascular history, and long-term adverse effects

Applying updated guidance
Newer biologics, AD guidelines, and nonpharmacologic care


Find this poster online

This activity is supported by an educational grant from Lilly.

DECERA CLINICAL Education

Find this program on our website

Broader Impact Among Target Learners



reported **intent to change practice** or **practice reinforcement** (n = 485)



expressed **confidence in making intended changes** (n = 470)

Top Intended Changes

1. **Advocate or contribute to TEAM change** to improve patient care, communication, or process
2. **Apply the latest guidelines** or research in this area
3. **Collaborate with other healthcare professionals** to incorporate learning into practice

Barriers to Implementing Change

48% of learners stated **cost restrictions** (insurance coverage, lack of prior authorization eligibility)

44% of learners stated **access** to therapies or diagnostics

27% of learners stated patient **adherence/ compliance**

Limitations

- Uneven geographic representation may limit generalizability.
- Confidence, intended practice changes, and barriers were self-reported.

Conclusion

- Multimodal CE in moderate to severe atopic dermatitis was associated with improved learner performance in evaluating therapeutic response, classifying biologic candidates and appraising biologic evidence.
- Although 45% reported greater likelihood of adopting patient-management principles, cost and access remain common implementation barriers.
- Future education should address learner questions about biologic selection, treatment switching and individualized safety, and practical guidance on navigating access barriers.

References
1. Chan KR, Keddie SH, Flohr C, et al. Prevalence of atopic dermatitis in the United States from 2021 to 2024: data from the National Health Interview Survey. J Am Acad Dermatol. 2026;94:633-635.
2. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90:e43-e56.
3. Ameen M, Meller S, Pinter A, et al. Perception and experience of biologic therapy in atopic dermatitis: a qualitative focus group study of physicians and patients in Europe and Canada. Dermatol Ther (Heidelb). 2021;11:2159-2177.